Neoplasms

All Conditions

Skin and Connective Tissue Diseases

Digestive System Diseases

Gland and Hormone Related Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Symptoms and General Pathology

Rare Diseases

Carcinoma

Breast Neoplasms

Pancreatic Neoplasms

Melanoma

Prostatic Neoplasms

Carcinoma, Squamous Cell

Sarcoma

Shock

Neoplasm Metastasis

Neoplastic Cells, Circulating

Neoplastic Processes

Pancreatic Cancer

Soft Tissue Sarcoma

All Drugs and Chemicals

Antibodies

Immunoglobulins

Isolation of circulating tumor cells by HSP70

patients will receive additional blood examinations with quantification of circulating tumor cells by HSP70 antibodies and EpCAM.

CTC isolation by HSP70

Sebastian Zschaeck, MD

Sebastian Zschaeck, M.D.

This study investigates the ability of heat shock protein HSP70 to isolate and quantify circulating tumor cells (CTCs) in patients with advanced or metastatic tumors.

CTCs will be isolated from peripheral blood before antineoplastic treatment and again after three months. Isolation using HSP70 will be compared with standard CTC isolation by EpCAM.

Additionally, imaging parameters of the primary tumor (if available) and metastases will be analysed and correlations between molecular alterations and imaging parameters will be assesed.

Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells

Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells in Patients With Advanced or Metastatic Tumors.

patients can sign an optional agreement that their pseudonymized imaging and genetic data will be shared on cancerimagingarchive.net

radiographic response to treatment will be scored according to RECIST criteria and associated with the number of CTC

the number of CTCs obtained by the novel HSP70 method will be compared to the current gold standard that uses EpCAM. This will be performed for the whole cohort and separate for each tumor site

computed tomography parameters of primary tumors and metastases will be analysed and parameters extraced that are differentially expressed between both. The same will be performed for genomic mutations and gene expression of the primary tumor and CTC. Correlation analyses will be performed to analyze if radiographic parameters resemble genetic alterations

Progression free survival will be evaluated with the number of CTC as variable. This will be performed for the whole cohort and separate for each tumor site

Overall survival will be evaluated with the number of CTC as variable. This will be performed for the whole cohort and separate for each tumor site

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells	NCT04628806	Melanoma Stage ... Sarcoma Squamous Cell C... Pancreatic Canc... Prostate Cancer Breast Cancer S...	CTC isolation b...	18 Years -	Charite University, Berlin, Germany
Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells	NCT04628806	Melanoma Stage ... Sarcoma Squamous Cell C... Pancreatic Canc... Prostate Cancer Breast Cancer S...	CTC isolation b...	18 Years -	Charite University, Berlin, Germany

Spots Global Cancer Trial Database for ctc isolation by hsp70